ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
25 announcements
SEBI issued an advisory letter to Sheel Biotech Limited for delayed disclosure of a monitoring agency report. No monetary penalty or restrictions were imposed on the company.
Sheel Biotech Limited held its 35th Annual General Meeting on September 24, 2026. The meeting covered adoption of financial statements and approval of other ordinary resolutions.
Sheel Biotech intimated that its Statutory Auditor Shyam Sunder Mangla & Co LLP has changed its name to S S Mangla & Co LLP effective 18 December 2025. No change in the auditor appointment itself.
Sheel Biotech Limited has finalised a commercial transaction for its Blueberry project, valued at ₹14.53 Crore. This contract marks a significant business development for the company.
Sheel Biotech Limited scheduled its 35th Annual General Meeting for September 24, 2026. The company also announced the record date and book closure period.
Sheel Biotech Limited submitted the Monitoring Agency Report for the half-year ended March 31, 2026, detailing the utilization of IPO proceeds as per SEBI regulations.
Sheel Biotech Limited has issued a notice for its 35th Annual General Meeting scheduled for September 24, 2026, to conduct routine business and special resolutions.
Sheel Biotech Limited has announced the outcome of its board meeting held on August 31, 2026, including the approval of the notice for its 35th AGM.
Sheel Biotech Limited has scheduled a board meeting for August 31, 2026, to discuss general business matters.
Sheel Biotech Limited secured a Rs. 21.39 Crore contract from J&K Agro Industries Development Corporation Limited. The project involves establishing five Centres of Excellence for precision farming.
Sheel Biotech Limited filed its Statement of Investor Complaints for the quarter ended June 30, 2026. The company reported nil pending complaints.
Sheel Biotech is pivoting into the high-margin blueberry market, targeting ₹110 Cr+ revenue for FY26 using its established tissue culture and greenhouse infrastructure.
Sheel Biotech Ltd reported revenue from operations of ₹88.2 Cr (-2.5% YoY) and net profit of ₹11.6 Cr (-20.0% YoY) for H2 FY26.
Sheel Biotech appointed Mr. Satbir Singh as CFO effective July 3, 2026. He brings 16 years of finance and audit experience to the role.
Sheel Biotech Limited reported a total income of ₹110.74 Crore for FY26. The board approved these audited results along with an unmodified audit report.
Sheel Biotech scheduled a board meeting on May 28, 2026, to approve annual audited financial results. The trading window remains closed until June 30.
Sheel Biotech signed an MoU with ICAR-CISH for technology commercialization in fruit innovation. This strategic partnership aims to enhance long-term growth and market positioning.
Sheel Biotech utilized ₹31.28 Crore of its ₹34.02 Crore IPO proceeds with zero deviation. Monitoring reports confirm the remaining funds are safely deployed in fixed deposits.
Sheel Biotech Limited submitted its annual Structured Digital Database (SDD) compliance certificate for the financial year ended March 31, 2026. Issued by Gulista & Associates, the certificate confirms the company maintains a non-tamperable database capturing all UPSI events as required by SEBI PIT Regulations.
Sheel Biotech Limited announced the resignation of its Chief Financial Officer, Anil Kumar, effective April 7, 2026. The company is now in the process of identifying a successor for the key managerial role.
Sheel Biotech Limited submitted a declaration stating that the requirement to file an Annual Secretarial Compliance Report for FY 2025-26 is not applicable. The company qualifies for this exemption as it is listed on the NSE SME Exchange. This is a routine regulatory update with no material financial impact.
Sheel Biotech Limited announced the resignation of Mr. Anil Kumar as Chief Financial Officer and Key Managerial Personnel, effective April 07, 2026. The departure is attributed to other professional commitments. The company is now required to appoint a successor to ensure leadership continuity in its financial operations.
Sheel Biotech Limited promoter Divye Chandak submitted a declaration confirming that the promoter group and persons acting in concert made no new encumbrances on their shares during the financial year ended March 31, 2026. This is a routine annual compliance filing under SEBI SAST Regulations.
Sheel Biotech Limited submitted its quarterly compliance certificate under Regulation 74(5) for the period ended March 31, 2026. The registrar, Skyline Financial Services, confirmed no physical shares were received for dematerialization during the quarter. This is a routine administrative disclosure for regulatory records.
Sheel Biotech Limited informed the National Stock Exchange that Corporate Governance Report filing requirements under Regulation 27(2) are not applicable to the company. As an entity listed on the NSE SME Platform, it claims exemption under Regulation 15(2) of SEBI LODR Regulations for the quarter ended March 31, 2026.